ArticleInternational journal of clinical and experimental medicine2015
Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Rationale for the Use of Fixed Combination Therapies with Angiotensin Converting Enzyme Inhibitors and Beta-Blockers in Patients with Essential Hypertension and High Cardiovascular Risk: A Consensus Document from the Italian Society of Arterial Hypertension (Siia) and the Italian Society of Cardiovascular Prevention (SIPREC).High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Guideline
- Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Pooled it
- Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension.Current hypertension reports · 2015Trial
- Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review, meta-analysis, and meta-regression.Annals of medicine and surgery (2012) · 2026Article
- Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?Current hypertension reports · 2019Review
- Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats.World journal of critical care medicine · 2018Article
- Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.American journal of nephrology · 2018Article
- A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence.Journal of general internal medicine · 2017Review
- Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.Vascular health and risk management · 2017Review
- Should All Patients with Resistant Hypertension Receive Spironolactone?Current hypertension reports · 2016Review
- Three drugs and still hypertensive: what's left?Canadian family physician Medecin de famille canadien · 2016Review
- New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.Current hypertension reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study sought to determine the current effectiveness and safety of spironolactone for resistant hypertension.
methodsPubmed, EMBASE and Cochrane databases were searched to identify studies that used spironolactone as add-on treatment in resistant hypertension patients. The major outcome is reduction of blood pressure.
resultsThree randomized controlled trials, 5 observational study without control group have been identified. At follow-up review, there was a reduction in mean systolic and diastolic blood pressure (BP) respectively, of -20.56 mmHg (95% confidence interval [CI]: -36.47 to -4.65 mmHg) and -6.04 mm Hg (95% CI: -10.24 to -1.85 mm Hg) in controlled study. In uncontrolled studies, at 6-month follow-up, systolic and diastolic BP were reduced -20.73 mm Hg (95% CI: -25.62 to -15.83 mm Hg) and -8.94 mm Hg (95% CI: -10.82 to -7.05 mm Hg, respectively.
conclusionSpironolactone resulted in the reduction of mean BP in patients with resistant hypertension. The sustained efficacy and safety of spironolactone need to further confirm by large randomized controlled trials with long-term follow-up.
Indexed as
Identifiers
26221266PMC4509211W2408837465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.